Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 19/20 | 0.74 |
| ▸ | RARA | P10276 | 18/20 | 0.74 |
| ▸ | RARG | P13631 | 18/20 | 0.74 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235546 | 0.93 | RARB (0.76) | RARBRARARARG | |
| SCHEMBL6244495 | 0.92 | RARB (0.80) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6239401 | 0.91 | RARB (0.75) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6240831 | 0.91 | RARA (0.76) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6234219 | 0.90 | RARB (0.77) | RARBRARARARG | |
| SCHEMBL6235406 | 0.90 | RARB (0.76) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL27489547 | 0.90 | RARB (0.70) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6235248 | 0.90 | RARA (0.76) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6236572 | 0.89 | RARB (0.76) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL6237238 | 0.89 | RARB (0.76) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6942980-B1 | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities | ALLERGAN, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1535919-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Allergan, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1042313-B1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST LIKE ACTIVITY | ALLERGAN INC (US) | 2004-04-28 | — | — | EP | disclosed |
| CN-1142928-C | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activity | �ո��� | 2004-03-24 | — | — | CN | disclosed |
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | KLEIN ELLIOTT S (US) | 2003-11-27 | — | — | US | disclosed |
| CN-1121379-C | Synthesis and use of retinoid having negative hormone and/or antagonist activity | ALLERGAN CO (US) | 2003-09-17 | — | — | CN | disclosed |
| EP-0931786-B1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-0853610-B1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6521624-B1 | Prevention or amelioration of toxicity or undesired side effect caused by a retinoid compound | ALLERGAN, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6469028-B1 | ARYL-SUBSTITUTED AND ARYL AND (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE, AND 5,6-DIHYDRONAPHTHALENE DERIVATIVES | ALLERGAN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-6228848-B1 | 3-(1-PROPEN-3-OXO)-5,6-DIHYDRONAPHTHALENE DERIVATIVES; SIDE EFFECT REDUCTION | ALLERGAN, INC. | 2001-05-08 | — | — | US | disclosed |
| US-6218128-B1 | DRUG SCREENING FOR INVERSE AGONIST BY MONITORING BINDING OF TWO POLYPEPTIDES HAVING SPECIFIC DOMAINS IN PRESENCE OF TEST COMPOUND | ALLERGAN SALES, INC. | 2001-04-17 | — | — | US | disclosed |
| US-6090810-A | SIDE EFFECT REDUCTION | ALLERGAN SALES, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6008204-A | ANTIDOTES FOR PREVENTING CERTAIN UNDESIRED SIDE EFFECTS OF RETINOIDS | ALLERGAN SALES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5952345-A | RETINOID ACID RECEPTOR ANTAGONIST; A DERIVATIVES OF ARYL-SUBSTITUTED AND ARYL (3-OXO-1-PROPENLY)-SUBSTITUTED BENZOPYRAN, BENZOTHIOPYRAN, 1,2-DIHYDROQUINOLINE; PREVENTING TOXICITY OR SIDE EFFECTS CAUSED BY RETINOIDS OR VITAMIN A | ALLERGAN SALES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0931786-A2 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | Vision Pharmaceuticals L.P. (US) | 1999-07-28 | — | — | EP | disclosed |
| CN-1209802-A | Synthesis and use of retinoid having negative hormone and/or antagonist activity | ALLERGAN CO (US) | 1999-03-03 | — | — | CN | disclosed |
| US-5877207-A | SKIN DISORDERS; ANTICARCINOGENIC AGENTS | ALLERGAN SALES, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| US-5776699-A | MEASURING GENE EXPRESSION | ALLERGAN, INC. (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219832-A1 | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | RXRA, RARA, RXRG | RARB 7/4885RARA 2/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.